文献速递甲状腺疾病

影像检查碘对比剂后碘致甲状腺功能亢进患病率的系统评价与荟萃分析

Prevalence of Iodine-Induced Hyperthyroidism After Administration of Iodinated Contrast During Radiographic Procedures: A Systematic Review and Meta-Analysis of the Literature.
PubMed 文献 · Thyroid · 2021-03-15

该系统评价与荟萃分析检索1946年至2018年5月的文献,纳入30项研究,评估碘对比剂暴露后甲亢的发生率。暴露后显性甲亢总体估计患病率极低,为0.1%(CI 0-0.6%),基线甲状腺功能正常者为0.3%(CI 0-1.7%)。结论认为影像检查使用碘对比剂后碘致甲亢发生率极低。

要点

  • 碘对比剂暴露后显性甲亢总体估计患病率极低,为0.1%(CI 0-0.6%)。
  • 基线甲状腺功能正常者暴露后显性甲亢估计患病率为0.3%(CI 0-1.7%)。
  • 暴露后7天无显性甲亢病例,30天发生率很低,为0.2%(CI 0-0.8%)。

核心结论

  • 影像检查中给予碘对比剂后,碘致甲亢的发生率极低。

研究设计与样本

  • 系统评价与荟萃分析,系统检索MEDLINE、Embase和Cochrane Library中1946年至2018年5月发表的研究。
  • 最终纳入30项研究,评估碘对比剂暴露与甲亢的关联,数据由两名评价者独立提取。

主要发现

  • 碘对比剂暴露后显性甲亢总体估计患病率为0.1%(CI 0-0.6%)。
  • 按基线甲状腺功能状态调整后结果不变,基线甲状腺功能正常者显性甲亢患病率为0.3%(CI 0-1.7%)。
  • 暴露后7天无显性甲亢病例,30天时发生率很低,为0.2%(CI 0-0.8%)。

关键数值与推荐

  • 各研究评估碘对比剂暴露后甲状腺激素水平的时间终点在1至541天之间,多数研究在7至56天之间。
  • 显性甲亢总体估计患病率为0.1%(CI 0-0.6%),基线甲状腺功能正常者为0.3%(CI 0-1.7%)。
  • 暴露后7天显性甲亢病例数为0,30天发生率为0.2%(CI 0-0.8%)。

临床怎么用

  • 影像检查使用碘对比剂后碘致甲亢总体风险极低,可据此评估临床监测的必要性。
  • 对基线甲状腺功能正常者,暴露后显性甲亢估计患病率仍低(0.3%,CI 0-1.7%)。

局限性

  • 各研究评估甲状腺激素水平的时间终点差异较大,介于1至541天之间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Iodine-induced hyperthyroidism (IIH) was a common issue in the early twentieth century after introduction of iodine supplementation in dietary salt. Currently, IIH is mostly encountered in Western countries as a consequence of radiographic procedures involving the administration of iodinated contrast media (ICM). However, little is known about the magnitude and clinical relevance of this issue. To assess the incidence of hyperthyroidism after ICM exposure, we performed a systematic review and meta-analysis of the literature. Methods: MEDLINE, Embase, and the Cochrane Library were systematically searched for studies published between 1946 and May 2018. Studies were considered eligible if they investigated the association between hyperthyroidism and iodinated contrast. Data on study design, baseline characteristics, and outcomes were extracted independently by two reviewers. Results: Thirty out of 1493 retrieved studies were included in the analysis. The time endpoint to assess thyroid hormone levels after ICM exposure varied between 1 and 541 days among studies, with most studies having a time endpoint between 7 and 56 days. The overall estimated prevalence of overt hyperthyroidism after ICM exposure was extremely low (0.1% [confidence interval, CI 0-0.6%]), and did not change after adjustments for baseline thyroid function status (0.3% in euthyroid patients at baseline [CI 0-1.7%]). There were no cases with overt hyperthyroidism at 7 days after ICM exposure, and the incidence was very low at 30 days (0.2% [CI 0-0.8%]). Conclusion: The incidence of IIH after ICM administration during radiographic procedures is extremely low.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Bervini S, Trelle S, Kopp P, et al. Prevalence of Iodine-Induced Hyperthyroidism After Administration of Iodinated Contrast During Radiographic Procedures: A Systematic Review and Meta-Analysis of the Literature. Thyroid. 2021. PMID: 33327840. doi:10.1089/thy.2020.0459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。